Sangamo announced it has treated the first patient in a Phase 1/2 clinical trial evaluating SB-FIX, the company’s investigational gene therapy for patients with hemophilia B.
Seven ways your gift to NHF will support people with bleeding disorders.
The data presented was from 33 patients who have completed five years of treatment with Jivi®.
The data from both studies confirmed the safety and sustained efficacy of Eloctate ® and Alprolix ® over four years of treatment.
NHF's research grants support a variety of disciplines and levels of expertise.
The two recommendations address gene therapy clinical trials, and use of emicizumab-kxwh.
This chapter includes new product approvals and Guelcher explains that ITI could be the solution to eradicate the inhibitor itself.
Each year, hundreds of new parents hear the words, “Your child has a bleeding disorder.” This can be frightening to parents, especially if there is no previous family history of the disorder.
UniQure recently announced initial clinical data from patients treated in an open-label phase IIb dose-confirmation study of AMT-061, the company’s investigational gene therapy treatment for patients with severe and moderately severe hemophilia B.
NHF, Impact Education and the Postgraduate Institute for Medicine offers accredited educational opportunties for healthcare providers on managing and treating females with bleeding disorders.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car